Solid Biosciences Inc is a life science company... Show more
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SLDB declined for three days, in of 379 cases, the price declined further within the following month. The odds of a continued downward trend are .
The 10-day RSI Indicator for SLDB moved out of overbought territory on December 05, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on January 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SLDB as a result. In of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for SLDB turned negative on December 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .
SLDB moved below its 50-day moving average on January 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for SLDB crossed bullishly above the 50-day moving average on December 08, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SLDB advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 140 cases where SLDB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.077) is normal, around the industry mean (30.106). P/E Ratio (0.000) is within average values for comparable stocks, (51.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.888). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (322.270).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SLDB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a developer of novel gene therapy platform for advancing disease
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| VMFGX | 506.86 | 2.41 | +0.48% |
| Vanguard S&P Mid-Cap 400 Growth Idx I | |||
| SSQSX | 15.45 | -0.03 | -0.19% |
| State Street Instl Small-Cap Equity Svc | |||
| WQAIX | 14.17 | -0.05 | -0.35% |
| Westwood Quality AllCap Institutional | |||
| VSIEX | 22.55 | -0.14 | -0.62% |
| JPMorgan International Equity I | |||
| MGFZX | 8.31 | -0.06 | -0.72% |
| MassMutual Global I | |||
A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with EDIT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To SLDB | 1D Price Change % | ||
|---|---|---|---|---|
| SLDB | 100% | -1.53% | ||
| EDIT - SLDB | 50% Loosely correlated | -1.88% | ||
| DSGN - SLDB | 49% Loosely correlated | +4.93% | ||
| RGNX - SLDB | 46% Loosely correlated | -0.20% | ||
| SYRE - SLDB | 45% Loosely correlated | -3.87% | ||
| BEAM - SLDB | 45% Loosely correlated | +2.55% | ||
More | ||||